Jun 10, 2025

Featuring perspectives from Dr Jessica J Lin and Dr Joel W Neal, including the following topics:

• Introduction: Actionable Genomic Alterations (0:00)
• ALK (9:49)
• ROS1 (22:22)
• HER2 (31:00)
• RET (38:52)
• NTRK (45:30)
• MET (46:31)
• Novel Targeted Strategies (49:09)
• BRAF (54:19)
• KRAS G12C (55:38)

CME information and select...

Jun 8, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 2: Therapeutic Approaches Targeting HER2, MET, BRAF and KRAS G12C — Joel W Neal, MD, PhD

CME information and select...

Jun 8, 2025

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Therapeutic Targets Beyond EGFR for Non-Small Cell Lung Cancer | Faculty Presentation 1: Therapeutic Approaches Targeting ALK, ROS1, RET, TRK and NRG1 — Jessica J Lin, MD

CME information and select...

May 18, 2025

Featuring perspectives from Dr Ramaswamy Govindan and Dr Stephen V Liu, including the following topics:

• Introduction (0:00)
• Management of Nonmetastatic Non-Small Cell Lung Cancer (NSCLC) without a Targetable Mutation — Dr Govindan (4:04)
• First- and Later-Line Therapy for Metastatic NSCLC without a Targetable Mutation...

Apr 20, 2025

Featuring perspectives from Dr Jonathan Goldman and Dr Natasha B Leighl, including the following topics:

• Introduction (0:00)
• Current Management of Nonmetastatic and Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Prof Leighl (1:42)
• Promising Novel Agents in Clinical Development; EGFR Exon 20...